In this episode, they explore the findings from the landmark CaPP3 trial, hear from a participant living with Lynch syndrome, and discuss how genomics could help shift healthcare from treatment to prevention.
Daily low-dose aspirin may significantly reduce bowel cancer risk in people with Lynch syndrome.
The podcast discusses results from the landmark CaPP3 clinical trial investigating aspirin for cancer prevention.
Earlier research found aspirin could reduce bowel cancer risk in people with Lynch syndrome by around 50%.
Lynch syndrome is an inherited condition that greatly increases the risk of bowel and several other cancers.
Genomic testing can identify people who may benefit from targeted prevention strategies like aspirin therapy.
Prevention is becoming an increasingly important role for genomic medicine—not just diagnosing disease.
Aspirin is inexpensive and widely available, making it a potentially accessible prevention option.
Aspirin is not suitable for everyone because long-term use can increase the risk of bleeding and other side effects.
People should only take aspirin for cancer prevention under medical advice. Regular bowel cancer screening remains essential, even for people taking aspirin.
Family genetic testing can identify relatives who may also have Lynch syndrome and benefit from surveillance and prevention.
The podcast highlights how combining genomics, screening, and preventive treatments could improve long-term health outcomes
https://www.genomicsengland.co.uk/podcasts/could-taking-aspirin-halve-the-risk-of-bowel-cancer
Lynch Syndrome Ireland 